ArticleBMC infectious diseases2021
The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Plasma 4-hydroxynonenal estimates severity and prognosis in patients with acute exacerbation of chronic obstructive pulmonary disease.Scientific reports · 2025Article
- Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department.Scientific reports · 2025Observational
- Associations of serum MANF with severity and prognosis in community-acquired pneumonia patients.Scientific reports · 2025Article
- Longitudinal relationships between serum ferritin and prognosis among severe community-acquired pneumonia patients.Frontiers in pharmacology · 2025Article
- Association of serum interleukin-2 with severity and prognosis in hospitalized patients with community-acquired pneumonia: a prospective cohort study.Internal and emergency medicine · 2024Article
- The value of surfactant protein a in evaluating the severity and prognosis in community-acquired pneumonia patients.BMC pulmonary medicine · 2024Article
- Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.Biomedicines · 2023Article
- S100A9 is indispensable for survival of pneumococcal pneumonia in mice.PLoS pathogens · 2023Article
- Associations of Serum Clara Cell Protein 16 with Severity and Prognosis in Adults with Community-Acquired Pneumonia.International journal of general medicine · 2023Article
- The association between serum complement C3a and severity in patients with community-acquired pneumonia.Frontiers in immunology · 2023Article
- Serum TRAIL predicts severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study.Internal and emergency medicine · 2022Article
- Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study.International journal of medical sciences · 2022Article
- Cross-sectional and longitudinal associations of serum Cysteine-rich 61 with severity and prognosis among community-acquired pneumonia patients in China.Frontiers in medicine · 2022Article
- Serum Level of 4-Hydroxynonenal in Community-Acquired Pneumonia: A Potential Biomarker for Severity and Prognosis.Frontiers in medicine · 2022Article
- Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study.BMC pulmonary medicine · 2021Article
- Associations of Serum Resistin With the Severity and Prognosis in Patients With Community-Acquired Pneumonia.Frontiers in immunology · 2021Article
- Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPrevious studies found that S100A9 may involve in the pathophysiology of community-acquired pneumonia (CAP). However, the role of S100A9 was unclear in the CAP. The goal was to explore the correlations of serum S100A9 with the severity and prognosis of CAP patients based on a prospective cohort study.
methodsA total of 220 CAP patients and 110 control subjects were recruited. Demographic and clinical data were collected. Serum S100A9 and inflammatory cytokines were measured.
resultsSerum S100A9 was elevated in CAP patients on admission. Serum S100A9 was gradually elevated parallelly with CAP severity scores. Additionally, inflammatory cytokines were increased and blood routine parameters were changed in CAP patients compared with control subjects. Correlation analysis found that serum S100A9 was positively associated with CAP severity scores, blood routine parameters (WBC, NLR and MON) and inflammatory cytokines. Further, logistic regression analysis demonstrated that there were positive associations between serum S100A9 and CAP severity scores. Besides, the prognosis of CAP was tracked. Serum higher S100A9 on the early stage elevated the death of risk and hospital stay among CAP patients.
conclusionSerum S100A9 is positively correlated with the severity of CAP. On admission, serum higher S100A9 elevates the risk of death and hospital stay in CAP patients, suggesting that S100A9 may exert a certain role in the pathophysiology of CAP and regard as a serum diagnostic and managing biomarker for CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.